Know Cancer

or
forgot password

Expression of T Immunoregulatory Proteins in ALK+ Anaplastic Large Cell Lymphoma (ALCL)


N/A
N/A
20 Years
Open (Enrolling)
Both
Lymphoma

Thank you

Trial Information

Expression of T Immunoregulatory Proteins in ALK+ Anaplastic Large Cell Lymphoma (ALCL)


OBJECTIVES:

- To determine the expression of immunoregulatory proteins including CD4, FOXP3 and CD276
in anaplastic large cell lymphoma (ALCL).

- To correlate the expression of these proteins with the levels of anaplastic lymphoma
kinase (ALK) autoantibodies in patient of ANHL0131.

OUTLINE: Archived tissue microarray samples are analyzed by mass spectrometry and validated
by Western blotting, flow cytometry, and IHC.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Diagnosis of anaplastic large cell lymphoma

- Tissue microarray samples available from the Cooperative Human Tissue Network (CHTN)

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- Not specified

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Expression of immunoregulatory proteins including CD4, FOXP3 and CD276 in ALCL

Safety Issue:

No

Principal Investigator

Megan S. Lim, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

C.S. Mott Children's Hospital at University of Michigan Medical Center

Authority:

United States: Federal Government

Study ID:

CDR0000701026

NCT ID:

NCT01366170

Start Date:

May 2011

Completion Date:

Related Keywords:

  • Lymphoma
  • childhood anaplastic large cell lymphoma
  • Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Large-Cell, Anaplastic

Name

Location